Published in J Virol on January 01, 1994
Absolute dependence on kappa B responsive elements for initiation and Tat-mediated amplification of HIV transcription in blood CD4 T lymphocytes. EMBO J (1995) 2.10
Evolution of a disrupted TAR RNA hairpin structure in the HIV-1 virus. EMBO J (1994) 1.74
C/EBP proteins activate transcription from the human immunodeficiency virus type 1 long terminal repeat in macrophages/monocytes. J Virol (1995) 1.64
Regulation of human immunodeficiency virus type 1 and cytokine gene expression in myeloid cells by NF-kappa B/Rel transcription factors. Microbiol Rev (1995) 1.63
Bioluminescence imaging. Proc Am Thorac Soc (2005) 1.61
Activation of human immunodeficiency virus transcription in T cells revisited: NF-kappaB p65 stimulates transcriptional elongation. J Virol (2001) 1.61
Efficient transcription and replication of simian immunodeficiency virus in the absence of NF-kappaB and Sp1 binding elements. J Virol (1996) 1.39
Cell cycle- and Vpr-mediated regulation of human immunodeficiency virus type 1 expression in primary and transformed T-cell lines. J Virol (1999) 1.39
CCAAT/enhancer binding protein (C/EBP) sites are required for HIV-1 replication in primary macrophages but not CD4(+) T cells. Proc Natl Acad Sci U S A (1997) 1.31
Monocyte maturation controls expression of equine infectious anemia virus. J Virol (1994) 1.29
Regulation of HIV-1 transcription in cells of the monocyte-macrophage lineage. Retrovirology (2009) 1.17
The ZiN/POZ domain of ZF5 is required for both transcriptional activation and repression. Nucleic Acids Res (1997) 1.04
Genotypic and phenotypic characterization of long terminal repeat sequences from long-term survivors of human immunodeficiency virus type 1 infection. J Virol (1997) 0.99
Identification of a replication-competent pathogenic human immunodeficiency virus type 1 with a duplication in the TCF-1alpha region but lacking NF-kappaB binding sites. J Virol (1997) 0.97
Permanent occupancy of the human immunodeficiency virus type 1 enhancer by NF-kappa B is needed for persistent viral replication in monocytes. J Virol (1996) 0.94
Human immunodeficiency virus type 1 induction mediated by genistein is linked to cell cycle arrest in G2. J Virol (1998) 0.94
Stromal down-regulation of macrophage CD4/CCR5 expression and NF-κB activation mediates HIV-1 non-permissiveness in intestinal macrophages. PLoS Pathog (2011) 0.92
The peri-kappa B site mediates human immunodeficiency virus type 2 enhancer activation in monocytes but not in T cells. J Virol (1995) 0.91
Sequences regulating tropism of human immunodeficiency virus type 1 for brain capillary endothelial cells map to a unique region on the viral genome. J Virol (1996) 0.89
Development of co-selected single nucleotide polymorphisms in the viral promoter precedes the onset of human immunodeficiency virus type 1-associated neurocognitive impairment. J Neurovirol (2011) 0.89
Programming of neurotoxic cofactor CXCL-10 in HIV-1-associated dementia: abrogation of CXCL-10-induced neuro-glial toxicity in vitro by PKC activator. J Neuroinflammation (2012) 0.86
Impact of Chromatin on HIV Replication. Genes (Basel) (2015) 0.75
Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells. Mol Cell Biol (1982) 116.75
An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature (1987) 19.23
Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B. Proc Natl Acad Sci U S A (1989) 11.76
The location of cis-acting regulatory sequences in the human T cell lymphotropic virus type III (HTLV-III/LAV) long terminal repeat. Cell (1985) 11.28
Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients. Proc Natl Acad Sci U S A (1986) 8.45
Activation of the AIDS retrovirus promoter by the cellular transcription factor, Sp1. Science (1986) 8.01
HIV-1 tat trans-activation requires the loop sequence within tar. Nature (1988) 6.87
Identification of a putative regulator of early T cell activation genes. Science (1988) 6.62
Human immunodeficiency virus type 1 LTR TATA and TAR region sequences required for transcriptional regulation. EMBO J (1989) 4.24
The Fos complex and Fos-related antigens recognize sequence elements that contain AP-1 binding sites. Science (1988) 4.15
Interactions of cellular proteins involved in the transcriptional regulation of the human immunodeficiency virus. EMBO J (1987) 4.14
Structural arrangements of transcription control domains within the 5'-untranslated leader regions of the HIV-1 and HIV-2 promoters. Genes Dev (1988) 3.51
Cellular transcription factors involved in the regulation of HIV-1 gene expression. AIDS (1992) 3.20
Human cytomegalovirus productively infects primary differentiated macrophages. J Virol (1991) 3.16
Follicular dendritic cells and virus-like particles in AIDS-related lymphadenopathy. Lancet (1984) 3.01
Functional roles for the TATA promoter and enhancers in basal and Tat-induced expression of the human immunodeficiency virus type 1 long terminal repeat. J Virol (1992) 2.93
Purification of the human immunodeficiency virus type 1 enhancer and TAR binding proteins EBP-1 and UBP-1. EMBO J (1988) 2.74
Detection of HTLV-III RNA in lungs of patients with AIDS and pulmonary involvement. JAMA (1986) 2.30
Repression of HIV-1 transcription by a cellular protein. Science (1991) 2.17
Role of SP1-binding domains in in vivo transcriptional regulation of the human immunodeficiency virus type 1 long terminal repeat. J Virol (1989) 2.14
Regulation of HIV-1 gene expression. FASEB J (1991) 2.01
TAR independent activation of the human immunodeficiency virus in phorbol ester stimulated T lymphocytes. EMBO J (1990) 2.00
Effects of long terminal repeat mutations on human immunodeficiency virus type 1 replication. J Virol (1989) 1.91
Tumor necrosis factor stimulates transcription of HIV-1 in human T lymphocytes, independently and synergistically with mitogens. J Immunol (1989) 1.87
Linker-scanning mutational analysis of the transcriptional activity of the human immunodeficiency virus type 1 long terminal repeat. J Virol (1991) 1.84
Molecular basis of latency in pathogenic human viruses. Science (1991) 1.74
A human binding site for transcription factor USF/MLTF mimics the negative regulatory element of human immunodeficiency virus type 1. Virology (1992) 1.72
Identification of cis-acting repressive sequences within the negative regulatory element of human immunodeficiency virus type 1. J Virol (1990) 1.70
A discrete cis element in the human immunodeficiency virus long terminal repeat mediates synergistic trans activation by cytomegalovirus immediate-early proteins. J Virol (1991) 1.62
Variable role of the long terminal repeat Sp1-binding sites in human immunodeficiency virus replication in T lymphocytes. J Virol (1991) 1.45
An in vitro transcription analysis of early responses of the human immunodeficiency virus type 1 long terminal repeat to different transcriptional activators. Mol Cell Biol (1991) 1.42
TAR-independent transactivation by Tat in cells derived from the CNS: a novel mechanism of HIV-1 gene regulation. EMBO J (1992) 1.39
T-cell-induced expression of human immunodeficiency virus in macrophages. J Virol (1990) 1.38
Specific NF-kappa B subunits act in concert with Tat to stimulate human immunodeficiency virus type 1 transcription. J Virol (1992) 1.34
Repeated B motifs in the human immunodeficiency virus type I long terminal repeat enhancer region do not exhibit cooperative factor binding. Proc Natl Acad Sci U S A (1988) 1.19
Induction of NF-KB during monocyte differentiation by HIV type 1 infection. J Immunol (1991) 1.10
Differences in transcriptional enhancers of HIV-1 and HIV-2. Response to T cell activation signals. J Immunol (1990) 1.07
Alternative pathway for induction of human immunodeficiency virus gene expression: involvement of the general transcription machinery. J Virol (1991) 1.00
The NF kappa B independent cis-acting sequences in HIV-1 LTR responsive to T-cell activation. J Acquir Immune Defic Syndr (1991) 0.98
A novel cis-acting element that controls transcription of human immunodeficiency virus type 1 DNA, depending on cell type. J Virol (1991) 0.87
Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med (1997) 12.08
Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients. Proc Natl Acad Sci U S A (1986) 8.45
Promoter-specific trans activation and repression by human cytomegalovirus immediate-early proteins involves common and unique protein domains. J Virol (1990) 4.24
Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. HIV Neurobehavioral Research Center Group. Ann Neurol (1997) 4.17
Characterization of V3 sequence heterogeneity in subtype C human immunodeficiency virus type 1 isolates from Malawi: underrepresentation of X4 variants. J Virol (1999) 4.16
Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell (1997) 3.99
Regulated expression of early and late RNAs and proteins from the human cytomegalovirus immediate-early gene region. J Virol (1989) 3.98
Detection of human cytomegalovirus in peripheral blood lymphocytes in a natural infection. Science (1985) 3.69
BEACHES: an observational system for assessing children's eating and physical activity behaviors and associated events. J Appl Behav Anal (1991) 3.61
Seven-day recall and other physical activity self-reports in children and adolescents. Med Sci Sports Exerc (1993) 3.57
Widespread presence of histologically occult cytomegalovirus. Hum Pathol (1984) 3.45
Dendritic injury is a pathological substrate for human immunodeficiency virus-related cognitive disorders. HNRC Group. The HIV Neurobehavioral Research Center. Ann Neurol (1997) 3.38
Human cytomegalovirus US3 impairs transport and maturation of major histocompatibility complex class I heavy chains. Proc Natl Acad Sci U S A (1996) 3.17
Human cytomegalovirus productively infects primary differentiated macrophages. J Virol (1991) 3.16
Human cytomegalovirus inhibits antigen presentation by a sequential multistep process. Proc Natl Acad Sci U S A (1996) 3.16
Predominant immediate-early transcripts of human cytomegalovirus AD 169. J Virol (1984) 3.15
Long-term infection and transformation of dermal microvascular endothelial cells by human herpesvirus 8. J Virol (1999) 3.02
The human cytomegalovirus chemokine receptor US28 mediates vascular smooth muscle cell migration. Cell (1999) 2.97
Fine mapping of an immunodominant domain in the transmembrane glycoprotein of human immunodeficiency virus. J Virol (1987) 2.97
Binding of transcription factors and creation of a large nucleoprotein complex on the human cytomegalovirus enhancer. Proc Natl Acad Sci U S A (1987) 2.89
DNA microarrays of the complex human cytomegalovirus genome: profiling kinetic class with drug sensitivity of viral gene expression. J Virol (1999) 2.80
Correlates of physical activity at home in Mexican-American and Anglo-American preschool children. Health Psychol (1993) 2.74
Empiric antimicrobial therapy of domestically acquired acute diarrhea in urban adults. Arch Intern Med (1990) 2.45
The enhancer domain of the human cytomegalovirus major immediate-early promoter determines cell type-specific expression in transgenic mice. J Virol (1996) 2.37
tat regulates binding of the human immunodeficiency virus trans-activating region RNA loop-binding protein TRP-185. Genes Dev (1991) 2.34
Synergy between medical informatics and bioinformatics: facilitating genomic medicine for future health care. J Biomed Inform (2004) 2.25
Role of SP1-binding domains in in vivo transcriptional regulation of the human immunodeficiency virus type 1 long terminal repeat. J Virol (1989) 2.14
Cytomegalovirus US2 destroys two components of the MHC class II pathway, preventing recognition by CD4+ T cells. Nat Med (1999) 2.08
Blood-brain barrier tight junction disruption in human immunodeficiency virus-1 encephalitis. Am J Pathol (1999) 2.07
Transcriptional regulation of the human cytomegalovirus major immediate-early gene is associated with induction of DNase I-hypersensitive sites. Mol Cell Biol (1986) 2.05
Hijacking and exploitation of IL-10 by intracellular pathogens. Trends Microbiol (2001) 2.03
Neurocognitive impairment is an independent risk factor for death in HIV infection. San Diego HIV Neurobehavioral Research Center Group. Arch Neurol (1997) 2.00
TAR independent activation of the human immunodeficiency virus in phorbol ester stimulated T lymphocytes. EMBO J (1990) 2.00
Human immunodeficiency virus infection of bone marrow endothelium reduces induction of stromal hematopoietic growth factors. Blood (1996) 1.98
HIV-1 infection in a man homozygous for CCR5 delta 32. Lancet (1997) 1.95
Global analysis of herpes simplex virus type 1 transcription using an oligonucleotide-based DNA microarray. J Virol (2000) 1.95
Localization of cytomegalovirus proteins and genome during fulminant central nervous system infection in an AIDS patient. J Neuropathol Exp Neurol (1986) 1.94
The human cytomegalovirus IE86 protein can block cell cycle progression after inducing transition into the S phase of permissive cells. J Virol (2000) 1.92
Do pathogens accelerate atherosclerosis? J Nutr (2001) 1.91
Diagnosis of AIDS by using a 12-amino acid peptide representing an immunodominant epitope of the human immunodeficiency virus. J Infect Dis (1987) 1.91
Serial magnetic resonance imaging of experimental atherosclerosis detects lesion fine structure, progression and complications in vivo. Nat Med (1995) 1.90
Alterations in binding characteristics of the human immunodeficiency virus enhancer factor. J Virol (1988) 1.88
Transformation of NIH 3T3 cells with cloned fragments of human cytomegalovirus strain AD169. J Virol (1982) 1.88
Analysis of methotrexate in human plasma by high-pressure liquid chromatography with fluorescence detection. Cancer Res (1977) 1.87
Human cytomegalovirus IE86 protein interacts with promoter-bound TATA-binding protein via a specific region distinct from the autorepression domain. J Virol (1993) 1.82
Coexpression of truncated human cytomegalovirus gH with the UL115 gene product or the truncated human fibroblast growth factor receptor results in transport of gH to the cell surface. Virology (1993) 1.81
Television's influence on children's diet and physical activity. J Dev Behav Pediatr (1989) 1.77
Radiographic findings of the National Cooperative Crohn's Disease Study. Gastroenterology (1979) 1.77
Regulation and tissue-specific expression of human cytomegalovirus. Curr Top Microbiol Immunol (1990) 1.76
Human immunodeficiency virus infection of human brain capillary endothelial cells occurs via a CD4/galactosylceramide-independent mechanism. Proc Natl Acad Sci U S A (1993) 1.73
Glycoprotein H-related complexes of human cytomegalovirus: identification of a third protein in the gCIII complex. J Virol (1997) 1.73
Prolonged suppressive antibiotic therapy for infected orthopedic prostheses. Clin Infect Dis (1998) 1.72
Exclusive and persistent use of the entry coreceptor CXCR4 by human immunodeficiency virus type 1 from a subject homozygous for CCR5 delta32. J Virol (1998) 1.69
Direct interaction of the human cytomegalovirus IE86 protein with the cis repression signal does not preclude TBP from binding to the TATA box. J Virol (1993) 1.68
Synthetic peptide immunoassay distinguishes HIV type 1 and HIV type 2 infections. Science (1987) 1.66
Reactivation of latent human cytomegalovirus in CD14(+) monocytes is differentiation dependent. J Virol (2001) 1.65
Interferon-gamma and tumor necrosis factor-alpha specifically induce formation of cytomegalovirus-permissive monocyte-derived macrophages that are refractory to the antiviral activity of these cytokines. J Clin Invest (1997) 1.62
A discrete cis element in the human immunodeficiency virus long terminal repeat mediates synergistic trans activation by cytomegalovirus immediate-early proteins. J Virol (1991) 1.62
The major immediate-early gene ie3 of mouse cytomegalovirus is essential for viral growth. J Virol (2000) 1.62
Murine cytomegalovirus infection down-regulates MHC class II expression on macrophages by induction of IL-10. J Immunol (1999) 1.62
Annexation of the interchromosomal space during viral infection. Nat Cell Biol (2000) 1.59
Interaction of the 72-kilodalton human cytomegalovirus IE1 gene product with E2F1 coincides with E2F-dependent activation of dihydrofolate reductase transcription. J Virol (1995) 1.59
Sequence homology and immunologic cross-reactivity of human cytomegalovirus with HLA-DR beta chain: a means for graft rejection and immunosuppression. J Virol (1988) 1.57
Energy and macronutrient intakes of elite figure skaters. J Am Diet Assoc (2001) 1.56
Enhancer requirement for murine cytomegalovirus growth and genetic complementation by the human cytomegalovirus enhancer. J Virol (1998) 1.56
Cell-specific activity of the modulator region in the human cytomegalovirus major immediate-early gene. Mol Cell Biol (1989) 1.55
Human cytomegalovirus persistently infects aortic endothelial cells. J Virol (1998) 1.55
A transdominant tat mutant that inhibits tat-induced gene expression from the human immunodeficiency virus long terminal repeat. Proc Natl Acad Sci U S A (1990) 1.55
trans-activation of viral enhancers including long terminal repeat of the human immunodeficiency virus by the hepatitis B virus X protein. Virology (1989) 1.55
Aerobic and anaerobic swimming performance of individual Atlantic cod. J Exp Biol (2000) 1.55
Growth kinetics of human cytomegalovirus are altered in monocyte-derived macrophages. J Virol (1995) 1.52
Thermally induced asthma and airway drying. Am J Respir Crit Care Med (1999) 1.52
Gossypiboma--the problem of the retained surgical sponge. Radiology (1978) 1.52
An isoform variant of the cytomegalovirus immediate-early auto repressor functions as a transcriptional activator. Virology (1992) 1.51
Role of human immunodeficiency virus and cytomegalovirus in AIDS encephalitis. Am J Pathol (1988) 1.49
Stimulation of NFkappa B activity by multiple signaling pathways requires PAK1. J Biol Chem (2000) 1.49
THE MILLER-ABBOTT TUBE AS AN ADJUNCT TO SURGERY OF SMALL INTESTINAL OBSTRUCTIONS. Ann Surg (1940) 1.49
Effects of dichlorodiphenyltrichloroethane (DDT) analogs and polychlorinated biphenyl (PCB) mixtures on 17beta-(3H)estradiol binding to rat uterine receptor. Biochem Pharmacol (1974) 1.48
T cell recognition of HIV synthetic peptides in a natural infection. J Immunol (1989) 1.47
Spatial analysis of the distribution of Ixodes dammini (Acari: Ixodidae) on white-tailed deer in Ogle County, Illinois. J Med Entomol (1992) 1.47
HIV-1 in trophoblastic and villous Hofbauer cells, and haematological precursors in eight-week fetuses. Lancet (1990) 1.45
Upstream regulatory regions required to stabilize binding to the TATA sequence in an adenovirus early promoter. Nucleic Acids Res (1987) 1.43
B- and T-lymphocyte responses to an immunodominant epitope of human immunodeficiency virus. J Virol (1988) 1.42
Effect of spectral shaping and content on loudness discomfort. J Am Acad Audiol (2001) 1.42
A comparative analysis of conservative versus surgical treatment of Morton's neuroma. J Am Podiatr Med Assoc (1989) 1.42
Inflammatory cells in transplanted kidneys are infected by human cytomegalovirus. Am J Pathol (1988) 1.41
Individual variation and repeatability in aerobic and anaerobic swimming performance of European sea bass, Dicentrarchus labrax. J Exp Biol (2010) 1.39
T-cell-induced expression of human immunodeficiency virus in macrophages. J Virol (1990) 1.38
The Caltrac accelerometer as a physical activity monitor for school-age children. Med Sci Sports Exerc (1990) 1.38
Effects of genital tract inflammation on human immunodeficiency virus type 1 V3 populations in blood and semen. J Virol (2000) 1.38
Lymphotoxins and cytomegalovirus cooperatively induce interferon-beta, establishing host-virus détente. Immunity (2001) 1.37
A novel mechanism for persistence of human cytomegalovirus in macrophages. J Virol (1996) 1.37